This is a routine executive reorganization with no financial shock. Monitor for the CFO search outcome and any associated disclosure; the CEO doubling as CFO is a temporary structure that may signal cost discipline or delayed hiring. The R&D-focused appointment of Miralles (who was already consulting on clinical/regulatory strategy) is a positive for pipeline execution but not a catalyst.
Price Chart
Executive Summary
Artiva Biotherapeutics announced a reorganization of its executive team: CFO Thad Huston is departing effective May 22, 2026 with a $135,000 severance; CEO Fred Aslan assumes the principal financial officer role; and Diego Miralles transitions from the Board to President and Head of R&D with a $600,000 salary and inducement equity grants of 232,500 options and 77,500 RSUs. The CFO departure without a named successor creates a temporary gap in financial leadership, though the CEO taking over the role suggests internal continuity.
Key Facts
- CFO Thad Huston agreed to separation effective May 22, 2026; no replacement named yet; receives ~$135,000 severance (3 months salary) plus COBRA.
- CEO Fred Aslan appointed as principal financial and accounting officer, adding to his CEO and board member roles.
- Diego Miralles resigned from the Board effective May 18, 2026 to become President and Head of R&D; receives $600,000 base salary, 45% target bonus, and inducement awards of 232,500 options + 77,500 RSUs.
- Board size reduced from 8 to 7 members following Miralles' departure.
- All separations stated as not resulting from any dispute or disagreement with the company.
Financial Impact
CFO severance of approximately $135,000 is immaterial relative to the company's $228M market cap; inducement equity grants represent potential dilution of roughly 0.3% of outstanding shares.
Risk Factors
- Lack of a permanent CFO may strain financial reporting bandwidth if the CEO is overextended.
- Inducement equity grants add modest dilution over the vesting period.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-229714 |
| Document: 0001193125-26-229714-index-headers.html | 0001193125-26-229714 |
| Document: 0001193125-26-229714-index.html | 0001193125-26-229714 |
| Document: 0001193125-26-229714.txt | 0001193125-26-229714 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 20d ago | 8-K | $10.14 $8.91 | ▼ −12.13% | ▼ −11.67% | $6.86 (−32.35%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▼ −3.43% | ▼ −2.83% | $6.86 (−36.42%) |
Sep 9, 2026 23d ago | Insider Cluster | $10.79 $10.42 | ▲ +3.43% | ▲ +2.83% | $6.86 (+36.42%) |
Sep 4, 2026 28d ago | Insider Cluster | $11.19 $10.88 | ▼ −2.77% | ▼ −2.22% | $6.86 (−38.70%) |
Aug 15, 2026 6w ago | Institutional Cluster | $11.74 $11.68 | ▼ −0.51% | ▲ +0.16% | $6.86 (−41.57%) |
Jul 31, 2026 8w ago | Insider Buy | $10.76 $11.07 | ▲ +2.88% | ▲ +1.08% | $6.86 (−36.25%) |
Jul 28, 2026 9w ago | Insider Buy | $10.53 $10.02 | ▼ −4.84% | ▼ −3.30% | $6.86 (−34.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access